INCUBATE
@incub8coalition
Followers
258
Following
177
Media
251
Statuses
1K
We foster innovation, safeguard advancements, and amplify the results of life sciences investment.
Joined February 2019
@johnbstanford joined a breakout session at @BIOConvention on how to align policies impacting drug development with unmet patient need, where he discussed how policy can support innovation in areas like cancer and rare diseases.
0
0
0
RT @AUTM: Venture Partners at CU Boulder is awarding up to $50,000 to early-stage therapeutic projects, helping researchers bridge the fund….
colorado.edu
Venture Partners at CU Boulder has announced the first recipients of a new translational funding program designed to advance promising, early-stage therapeutics
0
1
0
In @Forbes, @sallypipes cites Incubate's Life Sciences Investment Tracker in her column on how IRA price-setting chills investment in drug research and development.
forbes.com
Buried within the One Big Beautiful Bill Act is a provision that could improve or even save the lives of the 30 million Americans suffering from rare diseases.
0
0
0
In the latest episode of @MakingMedPod, @johnbstanford welcomes @nyahphengsitthy of @BLaw to discuss the latest shifts in drug pricing, FDA policy, and the unpredictable pace of the Trump administration. See the full episode on the @MakingMedPod YouTube.
0
0
3
RT @FierceBiotech: Since 2022, China biotechs have developed 639 first-in-class drug candidates, a staggering 360% increase from 137 candid….
fiercebiotech.com
International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and patent expirations continue to rise. | International companies are...
0
4
0
In the latest edition of @MakingMedPod, @johnbstanford explains why the Trump administration is considering tariffs on imported medicines and what it means for the life sciences industry and American patients.
0
0
0
A Leerink analysis shows prices for top-selling drugs fall 87-99% due to generic competition. In the DOJ and FTC's next listening session, government officials should explore how PBMs block access to these low-cost options.
leerink.com
Leerink Partners' Articles – sharing our deep expertise and experience in Healthcare to help fuel our customers' next breakthrough innovation.
0
0
0
RT @BSBHbyVT: The Inflation Reduction Act's (IRA) pill penalty is reshaping oncology pipelines, as early-stage funding for high-Medicare-ex….
0
1
0
In an interview with @statnews, @JFruehauf of Mission BioCapital, LabCentral, and BioLabs, warns that "we in the U.S. are questioning our desire to lead" in biotech -- a sector that the U.S. has led since the '70s.
statnews.com
A well-placed biotech investor says U.S. policies are straining life sciences startups — and more disruption is coming.
0
0
1
In this week's @MakingMedPod, Incubate's executive director, @johnbstanford discusses how President Trump views tariffs as leverage for negotiations with other nations more than the end goal, and why that mindset matters as a possible 200% tariff on pharmaceuticals looms ahead.
0
0
0
In the new episode of @MakingMedPod, @johnbstanford covers Trump's escalating tariffs -- what they mean for global trade, why medicines are in the crosshairs, and how they could increase the cost of drugs. See the full episode on the @MakingMedPod YouTube.
0
0
1
In his @PharmExec Q&A interview, @johnbstanford warns that proposals like Most Favored Nation drug pricing could disrupt the investment pipeline that fuels medical breakthroughs.
pharmexec.com
New rules places upon the pharma industry will have a significant impact on how investors view the industry.
0
0
0
New @LeerinkPartners research shows that prices for most top-selling drugs drop as much as 98% after about 13 years on the market. Fixing Medicare's pill penalty, as the EPIC Act proposes, would protect the market forces that drive life science innovation.
0
0
0
As regulatory uncertainty grows, early-stage biotech startups are concerned about dwindling investment and confidence in the sector. Read more about Incubate's survey of CEOs in @qz:
0
0
0
In the latest episode of @MakingMedPod, @johnbstanford unpacks what didn't make it into the One Big Beautiful Bill Act. He highlights the good, like the exclusion of a Most Favored Nation policy, and the disappointing, including the absence of the EPIC Act pill penalty fix.
0
0
0
Only one in 10 drugs that enter clinical trials ever make it to market -- and development costs can reach $2.6 billion per drug. Learn more about the complex path of drug discovery and what's shaping the future of medicine:
0
0
0
In the newest episode of @MakingMedPod, @johnbstanford discusses why the One Big Beautiful Bill Act is a pro-business bill and what notable inclusions like the ORPHAN Cures Act mean for the biotech community. Watch the full episode on YouTube:.
0
0
0
Want to know how federal policy is shaping the future of biotech? Explore Incubate's Life Sciences Investment Tracker, which explores the impacts of the IRA's pill penalty on investment and research nationwide:
0
0
1
A new episode of @MakingMedPod is here! In this episode, @johnbstanford breaks down what made it into the One Big Beautiful Bill Act - like the ORPHAN Cures Act -- and what didn't, including the EPIC Act and PBM reforms. See the full episode on the @MakingMedPod Youtube.
0
0
1